Sanofi is buying Inhibrx for $1.7 Billion

The addition brings a potential rare disease asset to Sanofi's pipeline for alpha-1 antitrypsin deficiency

Sanofi recently revealed its intention to acquire Inhibrx, a clinical-stage biopharmaceutical company. The deal is valued at approximately $1.7 billion, with the possibility of an additional cash consideration of around $296 million. The acquisition is scheduled to occur following the spin-off of non-INBRX-101 assets, including its immune-oncology pipeline, into New Inhibrx. In addition, New Inhibrx will keep its current workforce.

INBRX-101 is a human recombinant protein that has the potential to regulate serum alpha-1-antitrypsin (AAT) levels in patients with AAT deficiency (AATD), requiring fewer doses. AATD is a genetic rare disease characterized by low levels of AAT protein, leading to the progressive deterioration of lung tissue. INBRX-101 functions by blocking the activity of neutrophil elastase, an enzyme that can lead to harm in the lungs of individuals with AATD. According to a company press release, INBRX-101 has the potential to help patients by reducing inflammation and preventing further deterioration of lung function.

INBRX-101 has successfully completed a Phase I trial, showcasing promising outcomes in terms of safety and pharmacokinetics. Enrollment in a Phase II clinical trial is underway to further assess its potential as a treatment for AATD.

The inclusion of INBRX-101 in their rare disease portfolio highlights our commitment to developing unique and potentially superior products. INBRX-101 will be a valuable addition to our research and development efforts, as it aligns with our focus on rare diseases and immune-mediated respiratory conditions. This will allow us to better serve the underserved AATD patients and communities.

Source: Sanofi